About the Journal

Download [This article belongs to Volume - 140, Issue - 04]

Abstract : In patients with coronavirus disease 2019 (COVID-19), cardiac biomarkers have been linked to disease severity and mortality. Among COVID-19 patients in the hospital, heart damage is a common complication. We didn't know, however, whether or not NT-proBNP might predict the fate of patients with severe COVID-19. We aimed to evaluate the impact on severity of an early investigate of NT-proBNP as cardiac biomarkers in Iraqi patients with COVID-19. In a case-control study, 90 “COVID-19” patients and 90 healthy volunteers were compared. COVID-19 patients were categorized into mild/moderate, severe, and no survived patients categories based on the severity of their illness. Blood samples were taken from the sick and healthy groups, and all demographic and clinical characteristics were recorded. Enzyme-linked immunosorbent assay were used to evaluate BNP, and IL-6 levels. Spectrophotometers were used to determine the lipid profile and renal tests. The levels of (BNP) were significantly higher among groups of patients However, the level of (BNP) was significantly higher in non-survive and severe, mild cases of COVID-19 groups compared with healthy group. Serum (BNP) levels were significantly high in non-survive (125.44 ± 21.27) compared sever Patients (113.59 ± 33.11) compared with mild/moderate case of patients group (59.11 ± 19.42) and healthy (26.6 ± 9.32) (P <0.001). Indicating it to be an independent predictor in the coronavirus disease. Serum (BNP) levels were correlated a significant positively with Age, D-dimer, ferritin,,TG, LDL-C, and IL-6 levels. While, a significant negative correlated with TC, and Lymph.%. Serum (BNP) concentration were increased in sever and critical patients with COVID-19 compared with mild/moderate case. NT-proBNP might be an independent risk factor for in hospital death in patients with severe COVID-19.

Copyright © 2020 All rights reserved | Bulletin of National Institute of Health Sciences